JP2021519315A5 - - Google Patents

Info

Publication number
JP2021519315A5
JP2021519315A5 JP2020551992A JP2020551992A JP2021519315A5 JP 2021519315 A5 JP2021519315 A5 JP 2021519315A5 JP 2020551992 A JP2020551992 A JP 2020551992A JP 2020551992 A JP2020551992 A JP 2020551992A JP 2021519315 A5 JP2021519315 A5 JP 2021519315A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rna virus
condition
keratitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519315A (ja
JP7242696B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023977 external-priority patent/WO2019191026A2/en
Publication of JP2021519315A publication Critical patent/JP2021519315A/ja
Publication of JP2021519315A5 publication Critical patent/JP2021519315A5/ja
Priority to JP2023035224A priority Critical patent/JP7745584B2/ja
Application granted granted Critical
Publication of JP7242696B2 publication Critical patent/JP7242696B2/ja
Priority to JP2025076718A priority patent/JP2025118771A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551992A 2018-03-27 2019-03-26 5’-アデノシン二リン酸リボース(adpr)の使用方法 Active JP7242696B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023035224A JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2025076718A JP2025118771A (ja) 2018-03-27 2025-05-02 5’-アデノシン二リン酸リボース(adpr)の使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648585P 2018-03-27 2018-03-27
US62/648,585 2018-03-27
US201862693021P 2018-07-02 2018-07-02
US62/693,021 2018-07-02
PCT/US2019/023977 WO2019191026A2 (en) 2018-03-27 2019-03-26 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023035224A Division JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法

Publications (3)

Publication Number Publication Date
JP2021519315A JP2021519315A (ja) 2021-08-10
JP2021519315A5 true JP2021519315A5 (enExample) 2022-04-01
JP7242696B2 JP7242696B2 (ja) 2023-03-20

Family

ID=66647439

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020551992A Active JP7242696B2 (ja) 2018-03-27 2019-03-26 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2023035224A Active JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2025076718A Pending JP2025118771A (ja) 2018-03-27 2025-05-02 5’-アデノシン二リン酸リボース(adpr)の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023035224A Active JP7745584B2 (ja) 2018-03-27 2023-03-08 5’-アデノシン二リン酸リボース(adpr)の使用方法
JP2025076718A Pending JP2025118771A (ja) 2018-03-27 2025-05-02 5’-アデノシン二リン酸リボース(adpr)の使用方法

Country Status (5)

Country Link
US (4) US10946034B2 (enExample)
EP (2) EP4226971A1 (enExample)
JP (3) JP7242696B2 (enExample)
ES (1) ES2949441T3 (enExample)
WO (1) WO2019191026A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
CN111714619B (zh) * 2020-07-15 2023-03-14 上海市浦东新区人民医院 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用
CN112972453B (zh) * 2021-03-05 2022-04-15 中国人民解放军军事科学院军事医学研究院 MDL-800在制备抑制SARS-CoV-2病毒易感性药物中的应用
KR102789553B1 (ko) * 2021-09-07 2025-04-03 주식회사 펄스인마이어스 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
WO2025122455A1 (en) * 2023-12-04 2025-06-12 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr) for vegf modulation
WO2025259632A1 (en) * 2024-06-12 2025-12-18 Sirtsei Pharmaceuticals, Inc. Compositions and methods for treating retinal diseases or conditions
WO2026073064A1 (en) * 2024-09-30 2026-04-02 Invirsa, Inc. 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273826A (ja) * 1991-02-27 1992-09-30 Dainippon Ink & Chem Inc 抗rsウイルス剤
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja) 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
WO1999012951A1 (en) 1997-09-11 1999-03-18 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
DE60015734D1 (de) 1999-02-26 2004-12-16 Inspire Pharmaceuticals Durham Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation
WO2000077179A2 (en) 1999-06-16 2000-12-21 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
WO2003011885A1 (en) 2001-07-25 2003-02-13 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
US20030236217A1 (en) 2002-05-21 2003-12-25 Shalwitz Robert A. Treatment of mucositis
JP2005089450A (ja) 2003-08-11 2005-04-07 Fujisawa Pharmaceut Co Ltd Rsウィルスによる感染症の予防または治療剤
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
CA2609549A1 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2007054814A1 (en) 2005-11-14 2007-05-18 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
JP6072009B2 (ja) 2011-05-12 2017-02-01 フォーサイト・バイオセラピューティクス・インコーポレーテッド ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物
US20160287622A1 (en) 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)

Similar Documents

Publication Publication Date Title
JP2021519315A5 (enExample)
ES2553788T3 (es) 3,5-diamino-6-cloro-N-(N-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazino-2-carboxamida
JP2023071933A5 (enExample)
US5789391A (en) Method of treating sinusitis with uridine triphosphates and related compounds
JP6392241B2 (ja) 3,5−ジアミノ−6−クロロ−n−(n−(4−フェニルブチル)カルバムイミドイル)ピラジン−2−カルボキサミド化合物
EP0889728B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
JP6021117B2 (ja) エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
CN105073717B (zh) 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
JP2014518268A5 (enExample)
JP2018505192A5 (enExample)
ES2949441T3 (es) Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
BR112017005104B1 (pt) Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos
BR112013032771B1 (pt) dipeptídio quimicamente e metabolicamente estável possuindo potente atividade bloqueadora de canais de sódio
US20110054163A1 (en) P2y6 receptor agonists for treating lung diseases
JP2019505596A5 (enExample)
CN104955812B (zh) 经芳烷基和芳氧基烷基取代的上皮钠通道阻断化合物
HRP20211942T1 (hr) Medicinska uporaba 5'-adenozin difosfat riboze (adpr)
BR112018074532B1 (pt) Composição farmacêutica, aerossol, e, kit.
US20110166149A1 (en) Pteridine derivatives for treating respiratory disease
CN104507918A (zh) 用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法
US20030036527A1 (en) Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds
ES2239728T3 (es) Combinaciones farmaceuticas de agonistas del receptor de adenosina a-2a y del receptor adrenergico beta-2.
JP2023524064A5 (enExample)
WO2021253647A1 (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
EP1941883A1 (en) Use of sodium blockers for an early therapy of obstructive lung diseases